Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
about
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerOverview and management of cardiac adverse events associated with tyrosine kinase inhibitorsIncidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisAre VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Sidestream dark field imaging: the evolution of real-time visualization of cutaneous microcirculation and its potential application in dermatology.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080Preserved capillary density of dorsal finger skin in treated hypertensive patients with or without type 2 diabetes.Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.Common secondary causes of resistant hypertension and rational for treatmentSuppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialCardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewContrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humansTreatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.Changes in labial capillary density on ascent to and descent from high altitudeManagement of antiangiogenic therapy-induced hypertension.Efficacy and safety of angiogenesis inhibitors in small-cell lung cancerTherapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionThe effect of microvascular pattern alterations on network resistance in spontaneously hypertensive rats.Novel tyrosine kinase signaling pathways: implications in vascular remodeling.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational studyPhase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.VEGF inhibition, hypertension, and renal toxicityRegulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesBiological mechanisms of bevacizumab-associated adverse events.Angiogenesis and hypertension: an update.Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Mechanisms of antiangiogenic-induced arterial hypertension.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
P2860
Q24595773-246660F8-9BAE-4FE2-B450-CD402569264BQ26865766-E9BF1272-1B44-4F06-BDFE-824DD30E7F4DQ27003304-DF021737-A873-4182-9EA8-6562B4A1E065Q28085104-127213F1-357D-4976-8F78-4D45C8A6D3CBQ30250303-B4DE4F88-FB2C-4421-BEC0-F55E72967FD4Q33418555-56448D33-D883-4610-8EEC-031CAD642557Q33684042-42629061-6ABE-4C8B-87E1-00A88BD1A685Q33726894-1C1EFEEF-3A54-4C4B-AB75-4F1C28A0B122Q33828690-D25EB2AA-271E-4318-909A-E66170811798Q34063604-6AD9B3D2-BE28-454A-BD93-4699B368BFCAQ34266335-041EF032-52B6-4414-8FD1-2885AF7EF95AQ34403301-FB458BF0-80D8-48DB-91B7-B494FA8E647FQ34467460-3BCBE799-500F-43DC-848A-28E9B1D891AEQ34669789-3AB0E97E-70E1-4826-94CF-06639C6C4B90Q34803030-B51B3B11-C132-465E-99FE-4FD1357E7A27Q34916352-81B6B843-2D76-4312-9DA2-5F66595330D9Q34996468-97011ACC-A188-4231-966D-A071E56E2021Q35187848-46CA3DA4-C751-4CF8-B00B-D78F560D2D8CQ35346619-A4FD19D5-8AF0-4B26-8391-2559164B70C3Q35584543-D7B3D53B-7717-44E4-A2C7-042EF19474D3Q36100725-EB66147A-692E-403F-B74B-26488375AD05Q36106439-AB856486-D536-4A3F-B2C9-F24571FAD53AQ36164669-6CC5F2E2-E75E-4054-BCB4-8F18CB65F21DQ36170252-9061A749-E88A-4C64-A5F0-D8DA1277D43BQ36207730-32B2F9D8-FDEE-450A-94A3-80D1086ED855Q36678295-06DA6AFD-CAD7-4765-9D6B-C6417BB37591Q36716097-476578FA-09A4-4107-9FF7-2645009A0B49Q36720089-9D8E6B02-427A-4395-8630-7C494070F5D7Q36751861-065CCD7F-E99A-409F-9FBD-E295CE634D2EQ36858624-F380A90E-8EEC-49FD-852C-9C662B9089CCQ36977529-8D4250EF-0C83-4CAE-BDBF-7544604BA93CQ37046852-E238EB9E-A32F-45B6-B4E9-CE51CA9FD57FQ37103555-7DAD2B21-153C-4D49-A8A8-D47C1FBC7144Q37385797-3D5127B5-7CDA-4142-A6AB-94AE14498301Q37546065-83F8A22B-8E59-4792-9D63-8E84A2D65EABQ37579043-76665E04-A2C2-4D71-8B7C-D50B35361DACQ37698956-AE707A62-0856-4FE7-BDCA-DC92ED811B64Q37729290-1FFCD06F-903C-4E55-B28F-7DB40517AC81Q37863585-CC343A48-CE2F-4343-9A66-409E140B40C2Q37963823-D7AE23A8-6C8B-4F01-B624-5D17F5C518AE
P2860
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@ast
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@en
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@nl
type
label
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@ast
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@en
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@nl
prefLabel
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@ast
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@en
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@nl
P2093
P1476
Hypertension and rarefaction d ...... lecule angiogenesis inhibitor.
@en
P2093
Eelco de Koning
Hans Gelderblom
Hein Putter
Jos Op 't Roodt
Marcel Hovens
Neeltje Steeghs
Olaf Christensen
Prabhu Rajagopalan
P304
P356
10.1158/1078-0432.CCR-07-5050
P407
P577
2008-06-01T00:00:00Z